BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

Even as the major biotech indices creep toward new all-time highs, buysiders are hard-pressed to identify any major risks that could cause a downturn in the fourth quarter. At the same time, there are few...
BC Week In Review | Sep 1, 2014
Financial News

Bioniche completes follow-on

Bioniche Life Sciences Inc. (TSX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Date completed: 2014-08-22   Type: Follow-on   Raised: C$5 million ($4.6 million)   Shares: 21.8 million   Price: C$0.23 (unit)   Shares after...
BioCentury | Jun 9, 2014
Product Development

Bladder breakthrough

Based on Genentech Inc. 's Phase I data presented last week at the American Society of Clinical Oncology meeting, the Roche unit could see swift uptake of its anti- PD-L1 antibody in the underserved indication...
BC Week In Review | Jan 13, 2014
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Hired: Donald Olds as COO, formerly president and CEO of Presagia Corp.  ...
BC Week In Review | Jan 6, 2014
Company News

Agilis Biotherapeutics management update

Agilis Biotherapeutics LLC , Germantown, Md.   Business: Neurology, Gene/Cell therapy   Hired: George Zorich as CEO, formerly president of North American operations at Bioniche Pharma Holdings Ltd. , which Mylan Inc. acquired  ...
BC Extra | Jan 1, 2014
Company News

Agilis announces Intrexon deal, CEO and financing

Newco Agilis Biotherapeutics LLC (Germantown, Md.) announced a deal with synthetic biology company Intrexon Corp. (NYSE:XON), named a new CEO and said it raised $8 million on Tuesday. Agilis and Intrexon partnered to develop DNA-based...
BC Week In Review | Dec 16, 2013
Financial News

Bioniche financial update

Bioniche said the Australian Securities Exchange approved the company's application to delist from the exchange. The company expects to delist on ASX next half and will continue trading on the Toronto Stock Exchange. Bioniche Life...
BC Week In Review | Nov 11, 2013
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Hired: Michael Berendt as CEO, formerly president and CEO of Aegera Therapeutics Inc. , which Pharmascience Inc. acquired; he replaces Graeme McRae, who...
BC Week In Review | Oct 14, 2013
Clinical News

Urocidin regulatory update

Bioniche now plans to submit an NDS under Health Canada's Notice of Compliance with Conditions policy by June 30, 2014, for Urocidin to treat bladder cancer after the agency asked for a clinical assessment package...
BC Week In Review | Oct 7, 2013
Financial News

Bioniche completes private placement of units

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Date completed: 9/26/13   Type: Private placement of units   Raised: C$9.8 million ($9.5 million)   Units: 33.8 million   Price: C$0.29...
Items per page:
1 - 10 of 159
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

Even as the major biotech indices creep toward new all-time highs, buysiders are hard-pressed to identify any major risks that could cause a downturn in the fourth quarter. At the same time, there are few...
BC Week In Review | Sep 1, 2014
Financial News

Bioniche completes follow-on

Bioniche Life Sciences Inc. (TSX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Date completed: 2014-08-22   Type: Follow-on   Raised: C$5 million ($4.6 million)   Shares: 21.8 million   Price: C$0.23 (unit)   Shares after...
BioCentury | Jun 9, 2014
Product Development

Bladder breakthrough

Based on Genentech Inc. 's Phase I data presented last week at the American Society of Clinical Oncology meeting, the Roche unit could see swift uptake of its anti- PD-L1 antibody in the underserved indication...
BC Week In Review | Jan 13, 2014
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Hired: Donald Olds as COO, formerly president and CEO of Presagia Corp.  ...
BC Week In Review | Jan 6, 2014
Company News

Agilis Biotherapeutics management update

Agilis Biotherapeutics LLC , Germantown, Md.   Business: Neurology, Gene/Cell therapy   Hired: George Zorich as CEO, formerly president of North American operations at Bioniche Pharma Holdings Ltd. , which Mylan Inc. acquired  ...
BC Extra | Jan 1, 2014
Company News

Agilis announces Intrexon deal, CEO and financing

Newco Agilis Biotherapeutics LLC (Germantown, Md.) announced a deal with synthetic biology company Intrexon Corp. (NYSE:XON), named a new CEO and said it raised $8 million on Tuesday. Agilis and Intrexon partnered to develop DNA-based...
BC Week In Review | Dec 16, 2013
Financial News

Bioniche financial update

Bioniche said the Australian Securities Exchange approved the company's application to delist from the exchange. The company expects to delist on ASX next half and will continue trading on the Toronto Stock Exchange. Bioniche Life...
BC Week In Review | Nov 11, 2013
Company News

Bioniche management update

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Hired: Michael Berendt as CEO, formerly president and CEO of Aegera Therapeutics Inc. , which Pharmascience Inc. acquired; he replaces Graeme McRae, who...
BC Week In Review | Oct 14, 2013
Clinical News

Urocidin regulatory update

Bioniche now plans to submit an NDS under Health Canada's Notice of Compliance with Conditions policy by June 30, 2014, for Urocidin to treat bladder cancer after the agency asked for a clinical assessment package...
BC Week In Review | Oct 7, 2013
Financial News

Bioniche completes private placement of units

Bioniche Life Sciences Inc. (TSX:BNC; ASX:BNC), Belleville, Ontario   Business: Cancer, Agbio/Environmental   Date completed: 9/26/13   Type: Private placement of units   Raised: C$9.8 million ($9.5 million)   Units: 33.8 million   Price: C$0.29...
Items per page:
1 - 10 of 159